Evidence map›Paper›PMID 29320578›Full record

ArticlePLoS pathogens2018

The potent effect of mycolactone on lipid membranes.

Milène Nitenberg, Anaïs Bénarouche, Ofelia Maniti, Estelle Marion, Laurent Marsollier, Julie Géan, Erick J Dufourc, Jean-François Cavalier, Stéphane Canaan, Agnès P Girard-Egrot

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Significance of extracellular vesicles in orchestration of immune responses inFrontiers in cellular and infection microbiology · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. The conical shape of DIM lipids promotesProceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Milène NitenbergUniv. Lyon, Université Lyon 1, CNRS, Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, ICBMS-UMR 5246, GEMBAS team, Lyon, France.
Anaïs BénaroucheAix-Marseille Univ, CNRS, EIPL, Marseille, France.
Ofelia ManitiUniv. Lyon, Université Lyon 1, CNRS, Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, ICBMS-UMR 5246, GEMBAS team, Lyon, France.
Estelle MarionCRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.
Laurent MarsollierCRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.
Julie GéanUniv. Bordeaux, CNRS, Bordeaux INP, Chemistry and Biology of Membranes and Nano-objects, CBMN UMR 5248, Pessac, France.ORCID 0000-0002-6342-5562
Erick J DufourcUniv. Bordeaux, CNRS, Bordeaux INP, Chemistry and Biology of Membranes and Nano-objects, CBMN UMR 5248, Pessac, France.
Jean-François CavalierAix-Marseille Univ, CNRS, EIPL, Marseille, France.ORCID 0000-0003-0864-8314
Stéphane CanaanAix-Marseille Univ, CNRS, EIPL, Marseille, France.
Agnès P Girard-EgrotUniv. Lyon, Université Lyon 1, CNRS, Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, ICBMS-UMR 5246, GEMBAS team, Lyon, France.ORCID 0000-0003-2612-3124
Centre National de la Recherche Scientifique · FRUniversité Claude Bernard Lyon 1 · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mycolactone is a lipid-like endotoxin synthesized by an environmental human pathogen, Mycobacterium ulcerans, the causal agent of Buruli ulcer disease. Mycolactone has pleiotropic effects on fundamental cellular processes (cell adhesion, cell death and inflammation). Various cellular targets of mycolactone have been identified and a literature survey revealed that most of these targets are membrane receptors residing in ordered plasma membrane nanodomains, within which their functionalities can be modulated. We investigated the capacity of mycolactone to interact with membranes, to evaluate its effects on membrane lipid organization following its diffusion across the cell membrane. We used Langmuir monolayers as a cell membrane model. Experiments were carried out with a lipid composition chosen to be as similar as possible to that of the plasma membrane. Mycolactone, which has surfactant properties, with an apparent saturation concentration of 1 μM, interacted with the membrane at very low concentrations (60 nM). The interaction of mycolactone with the membrane was mediated by the presence of cholesterol and, like detergents, mycolactone reshaped the membrane. In its monomeric form, this toxin modifies lipid segregation in the monolayer, strongly affecting the formation of ordered microdomains. These findings suggest that mycolactone disturbs lipid organization in the biological membranes it crosses, with potential effects on cell functions and signaling pathways. Microdomain remodeling may therefore underlie molecular events, accounting for the ability of mycolactone to attack multiple targets and providing new insight into a single unifying mechanism underlying the pleiotropic effects of this molecule. This membrane remodeling may act in synergy with the other known effects of mycolactone on its intracellular targets, potentiating these effects.

Indexed as

Lipid BilayersBuruli UlcerCell AdhesionHumansMacrolidesMembrane LipidsMembrane MicrodomainsMicrobial Sensitivity TestsMycobacterium ulceransSurface-Active AgentsLipid BilayersMacrolidesMembrane LipidsmycolactoneSurface-Active Agents

Identifiers

PMID29320578
PMCPMC5779694
OpenAlexW2782883240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.